Citius Oncology Announces Positive Topline Results from Investigator?Initiated Phase 1 Study of LYMPHIR(TM) in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Oncology Expands International Distribution of LYMPHIR(TM) to European Union Through Exclusive Agreement with Uniphar
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Expands LYMPHIR(TM) Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.